| symbol |
CNST |
|---|
| 会社名 | Constellation Pharmaceuticals Inc （コンステレ―ション・ファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Constellation Pharmaceuticals Inc. is a United States-based company which discovers and develops small molecule therapeutics for the treatment of cancer inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound CPI-0610 and the other program is evaluating a compound CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma and a Phase 1 clinical study of CPI-1205 in patients with lymphoma. コンステレ―ション・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、異常な遺伝子発現や薬剤耐性に起因するがん患者の治療薬の開発に従事する。同社の医薬品候補CPI-1205は、アンドロゲン受容体シグナル伝達阻害剤と組み合わせた前立腺がんの治療、免疫と組み合わせた固形がんの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。 Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
|
|---|
| 本社所在地 | 215 First Street Suite 200 Cambridge MA 02142 USA |
|---|
| 代表者氏名 | Mark A. Goldsmith マークA.ゴールドスミス |
|---|
| 代表者役職名 | Executive Chairman Venture Partner |
|---|
| 電話番号 | +1 617-714-0555 |
|---|
| 設立年月日 | 39448 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2018年 |
|---|
| 従業員数 | － |
|---|
| url | www.constellationpharma.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/cnst |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -45.22600 |
|---|
| 終値（lastsale） | 6.78 |
|---|
| 時価総額（marketcap） | 174373667.4 |
|---|
| 時価総額 | 時価総額（百万ドル） 174.88800 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 360.13900 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -55.62300 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Constellation Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 8% to $24M. Higher net loss reflects FV Adjustments of Financial Investments decrease from $4.4M (income) to $0K Research and development - Balancing increase of 29% to $18.9M (expense) General and administrative - Balanci increase of 66% to $2.3M (expense). |
|---|
CNST - コンステレ―ション・ファ―マシュ―ティカルズ （Constellation Pharmaceuticals Inc.） コンステレ―ション・ファ―マシュ―ティカルズ